Background
The STAT3 signaling pathway
The STAT3 signaling pathway in triple negative breast cancer
Role of STAT3 in TNBC cell proliferation and anti-apoptosis
Role of STAT3 in TNBC cell migration and invasion
Role of STAT3 in angiogenesis of TNBC
Role of STAT3 in chemoresistance of TNBC
Role of STAT3 in immune suppression
Role of STAT3 in TNBC stem cell phenotypes
Role of STAT3 in autophagy of TNBC cells
Targeting STAT3 for TNBC prevention and therapy
Inhibitors | Mechanisms of action | In vitro activity | In vivo activity | Reference |
---|---|---|---|---|
Strategy 1: Target upstream regulators of STAT3
| ||||
Carfilzomib | Inhibits IL-6/STAT3 signaling pathway | Inhibits mitosis and proliferation and induces apoptosis | Reduces serum IL-6 levels in tumor-bearing mice | [87] |
Manuka honey | Inhibits IL-6/STAT3 signaling pathway | Inhibits cell viability and colony formation, induces apoptosis, impairs cell migration and invasion, and inhibits angiogenesis | NR | [88] |
Bazedoxifene | Inhibits IL6/gp130/STAT3 signaling pathway | Inhibits cell viability, colony formation and cell migration and synergistically enhances the activity of paclitaxel | Suppresses tumor growth | |
Ganoderma lucidum extract | Inhibits IL-6/JAK/STAT3 signaling pathway | Inhibits cell viability and induces apoptosis | Suppresses tumor growth | [91] |
Arsenic trioxide | Inhibits EZH2/NF-κB/IL-6/STAT3/VEGF signaling pathway | Inhibits angiogenesis | NR | [96] |
Deguelin | Inhibits EGFR/STAT3 signaling pathway | Inhibits cell viability | Suppresses tumor growth | [92] |
Picrasidine G | Inhibits EGFR/STAT3 signaling pathway | Inhibits cell viability and induces apoptosis | NR | [93] |
Cantharidin | Inhibits EGFR/STAT3 signaling pathway | Inhibits cell viability and induces apoptosis | NR | [94] |
Silibinin | Inhibits JAK2/STAT3/MMP2 signaling pathway | Inhibits cell viability, migration and invasion | NR | [97] |
Inhibits EGFR/STAT3/Fibronectin signaling pathway | NR | NR | [95] | |
Ganoderic acid A | Inhibits JAK2/STAT3 signaling pathway | Inhibits cell viability and invasive capacity and induces apoptosis | NR | [98] |
Nintedanib | Modulates SHP-1/p-STAT3 signaling pathway | Inhibits cell viability and induces apoptosis | Suppresses tumor growth | [99] |
SC-78 | Modulates SHP-1/p-STAT3/VEGF-A signaling pathway | Inhibits cell migration and tube formation | Suppresses tumor growth and metastasis | [100] |
1,2,3,4,6-penta-O-galloyl-beta-D-glucose | Modulates SHP-1/p-STAT3 signaling pathway | NR | Suppresses tumor growth and metastasis | [101] |
SC-2001 | Modulates RFX-1/SHP-1/p-STAT3 signaling pathway | Inhibits cell growth and induces apoptosis | Suppresses tumor growth | |
Isolinderalactone | Enhances SOCS3-mediated STAT3 dephosphorylation | Inhibits cell viability and colony formation and induces apoptosis | Suppresses tumor growth | [103] |
Compound 57 | Binds to HSP90 and inhibits the expression and phosphorylation of STAT3 | Inhibits cell viability | NR | [104] |
L80 | Binds to HSP90 and inhibits the expression and phosphorylation of STAT3 | Inhibits cell viability induces apoptosis, and suppresses BCSC-like properties | Suppresses the growth of BCSC-enriched TNBC tumors and distant metastasis | [105] |
Nor-wogonin | Inhibits TAK1-mediated STAT3 activation | Inhibits cell viability and proliferation and induces G1 and G2/M phases arrest and apoptosis | NR | [106] |
Thioridazine | Inhibits DRD2-mediated STAT3 activation | Inhibits cell self-renewal, proliferation, and viability and induces G1 arrest | NR | [107] |
Strategy 2: Directly bind to STAT3 and inhibit its activation
| ||||
Bt354 | Directly binds to SH2 domain of STAT3 and inhibits its phosphorylation | Inhibits cell viability, induces G2/M phase arrest and apoptosis, and impairs cell migration | Suppresses tumor growth | [108] |
Osthole | Directly binds to STAT3 and inhibits its phosphorylation | Inhibits cell viability and induces G2/M phase arrest and apoptosis | Suppresses tumor growth | [109] |
Arctigenin | Directly binds to SH2 domain of STAT3 and inhibits its phosphorylation and DNA binding ability | Inhibits cell viability, induces apoptosis, impairs cell migration and invasion, and sensitizes cells to chemotherapy | Suppresses tumor growth | [110] |
Alantolactone | Directly binds to SH2 domain of STAT3 and inhibits its phosphorylation | Inhibits cell viability and colony formation and impairs cell migration and invasion | Suppresses tumor growth | [111] |
KYZ3 | Directly binds to SH2 domain of STAT3 and inhibits its phosphorylation | Inhibits cell viability, induces apoptosis, and impairs cell migration | Suppresses tumor growth | [113] |
Strategy 3: Inhibit STAT3 phosphorylation or acetylation
| ||||
Sesquiterpene lactones fraction of Inula helenium L. | Inhibits STAT3 phosphorylation and nuclear translocation | Inhibits cell viability and induces apoptosis | Suppresses tumor growth | [114] |
Rhus coriaria | Inhibits STAT3 phosphorylation | Inhibits angiogenesis and impairs cell migration and invasion | Suppresses tumor growth and metastasis | [115] |
Schisandrin B | Inhibits STAT3 phosphorylation and nuclear translocation | Inhibits cell viability and colony formation, induces cell cycle arrest and apoptosis, and impairs cell migration | Suppresses tumor growth | [116] |
Eupalinolide J | Inhibits STAT3 phosphorylation and activation | Inhibits cell viability | NR | [117] |
Galiellalactone analogues 16 and 17 | Inhibits STAT3 phosphorylation and activation | Inhibits cell viability | NR | [118] |
FZU-03,010 | Inhibits STAT3 phosphorylation and activation | Inhibits cell viability and induces G1 phase arrest and apoptosis | NR | [119] |
Niclosamide | Inhibits STAT3 phosphorylation and nuclear translocation | Reverses acquired radioresistance | Sensitizes tumors to irradiation | [120] |
Flubendazole | Inhibits STAT3 phosphorylation | Inhibits cell viability, induces G2/M phase arrest and apoptosis, and suppresses BCSC-like phenotype | Suppresses tumor growth, angiogenesis and metastasis | [121] |
Disulfiram | Inhibits STAT3 expression and phosphorylation | Inhibits cell viability, induces apoptosis, and impairs cancer stem cell-like properties | Suppresses tumor growth and BCSC-like properties | [122] |
Salinomycin | Inhibits STAT3 phosphorylation and activation | Inhibits cell viability, promotes anoikis, impairs cell migration and invasion, and decreases CD44+/CD24− stem-like population | NR | [123] |
Metformin | Inhibits STAT3 phosphorylation | Inhibits cell viability | NR | [124] |
SH-I-14 | Inhibits STAT3 acetylation and disrupts DNMT1-STAT3 interaction | Inhibits cell viability | Suppresses tumor growth | [126] |
Strategy 4: Block STAT3-DNA binding
| ||||
Methylsulfonyl-methane | Inhibits the bindings of STAT3 to VEGF promoter and STAT5 to IGF-1R promoter | Inhibits cell viability and induces apoptosis | Suppresses tumor growth | [127] |
Isoharringtonine | Inhibits STAT3-mediated Nanog expression | Inhibits cell viability, impairs cell migration, and decreases proportion of BCSC population | NR | [128] |
Salidroside | Inhibits the bindings of STAT3 to MMP2 promoter | Inhibits cell migration, invasion and angiogenesis | NR | [129] |
Target upstream regulators of STAT3
Directly bind to STAT3 and inhibit its activation
Inhibit STAT3 phosphorylation or acetylation
Block STAT3-DNA binding
Inhibitors | Target | ClinicalTrials ID | Condition or disease | Phase | References |
---|---|---|---|---|---|
STAT3 DECOY | STAT3 | NCT00696176 | Head and neck cancer | Early phase 1 | [130] |
AZD9150 (IONIS-STAT3Rx or ISIS-STAT3Rx) | STAT3 | NCT01563302 | Advanced cancers, DLBCL | Phases 1 & 2 | |
NCT02417753 | Ovarian cancer, GIC | Phase 2 | |||
NCT01839604 | HCC | Phase 1 | |||
NCT02983578 | GIC, lung cancer, etc. | Phase 2 | |||
NCT03527147 | NHL, DLBCL, NHL, DLBCL | Phase 1 | |||
NCT02549651 | DLBCL | Phase 1 | |||
NCT03421353 | Advanced solid tumors | Phases 1 & 2 | |||
TTI-101 (C188–9) | STAT3 | NCT03195699 | Breast cancer, HNSCC, NSCLC, etc. | Phase 1 | [133] |
OPB-51602 | STAT3 | NCT02058017 | Nasopharyngeal carcinoma | Phase 1 | [134] |
NCT01867073 | Advanced solid tumors | Phase 1 | |||
NCT01423903 | Advanced cancer | Phase 1 | |||
OPB-31121 | STAT3 | NCT00955812 | Advanced cancer, solid tumor | Phase 1 | [136] |
OPB-111077 | STAT3 | NCT01711034 | Solid tumors | Phase 1 | [137] |
Napabucasin (BBI608 or GB201) | STAT3 | NCT03647839 | MCC | Phase 2 | [135] |
NCT03522649 | Previously treated MCC | Phase 3 | |||
NCT02826161 | NSCLC | Phase 3 | |||
NCT02993731 | Pancreatic ductal carcinoma | Phase 3 | |||
Pyrimethamine | STAT3 | NCT01066663 | CLL, SLL | Phases 1 & 2 | [138] |
NCT03057990 | Myelodysplastic syndromes | Phase 1 | |||
Simvastatin | STAT3 | NCT02390843 | Retinoblastoma, clear cell sarcoma, renal cell carcinoma, rhabdoid tumor, etc. | Phase 1 | [139] |
DSP-0337 | STAT3 | NCT03416816 | Neoplasms | Phase 1 | [140] |
Cetuximab | EGFR | NCT01445405 | Squamous carcinoma, head and neck cancer, etc. | Phase 1 | [141] |
Lapatinib | EGFR | NCT00105950 | Breast neoplasms | Phase 2 | [142] |
Dasatinib | c-Src | NCT02680951 | AML | Phase 1 | [143] |
SC-43 | SHP-1 | NCT03443622 | Refractory solid tumor | Phase 1 | [144] |
ASN002 | JAK | NCT02440685 | Lymphoma, leukemia | Phases 1 & 2 | [145] |
SAR302503 | JAK2 | NCT01420783 | Hematopoietic neoplasm | Phase 2 | [146] |
AZD1480 | JAK2 | NCT01112397 | Solid malignancies | Phase 1 | [147] |
WP1066 | JAK2 | NCT01904123 | Metastatic melanoma, recurrent glioblastoma, etc. | Phase 1 | [148] |